Clinical trials: Plaque
Plaque Psoriasis
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
This Phase 3 study has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT02367911
- Testing
- 122-0551 Foam, Vehicle Foam
- Where
- 9 sites in United States
- Volunteers
- 144 people
- Sponsor
- Therapeutics, Inc.
Plaque Psoriasis
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
The primary objective of the study is to assess the efficacy and safety of the combination of apremilast plus topical therapies for the treatment of adults with plaque psoriasis who have not achieved an adequate response with…
- Trial name
- NCT03930186
- Testing
- Apremilast, Topical Therapy
- Where
- 56 sites in Germany, Japan
- Volunteers
- 152 people
- Sponsor
- Amgen
Dental Plaque, Gingivitis
A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
The aim of this study is to assess the ability of a marketed Cetylpyridinium Chloride (CPC) mouthwash alongside a marketed Stannous Fluoride (SnF2) toothpaste in improving gingival health and reducing plaque accumulation…
- Trial name
- NCT06660069
- Testing
- Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste), CPC Mouthwash (Parodontax Active Gum Health Mouthwash), Regular Fluoride Toothpaste (Crest Cavity Protection)
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- HALEON
Psoriasis
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02850965
- Testing
- BI 695501, Humira
- Where
- 54 sites in United States, Czechia and 6 more
- Volunteers
- 318 people
- Sponsor
- Boehringer Ingelheim
Gingival Diseases
Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.
Clinical research study to determine the anti-plaque efficacy of prototype dentifrices via a 4-day brushing regiment
- Trial name
- NCT00966953
- Testing
- Fluoride, Triclosan/Fluoride toothpaste, antibacterial plant extract
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Psoriasis, Plaque Psoriasis
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPACT (NCT02346240)
- Testing
- Certolizumab Pegol, Etanercept
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 559 people
- Sponsor
- UCB Biopharma S.P.R.L.
Psoriasis
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with…
- Trial name
- REFINE (NCT01313221)
- Testing
- etanercept, Topical agents
- Where
- 24 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Amgen
Psoriasis
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type…
- Trial name
- POLARIS (NCT02951533)
- Testing
- Guselkumab, Fumaric Acid Esters
- Where
- 28 sites in Germany
- Volunteers
- 119 people
- Sponsor
- Janssen-Cilag G.m.b.H
Psoriasis
Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy
The purpose of this study is to evaluate the use of etanercept as a replacement therapy for ciclosporin in patients with plaque psoriasis.
- Trial name
- NCT00581555
- Testing
- Etanercept
- Volunteers
- 120 people
- Sponsor
- Pfizer
Plaque Psoriasis
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.
- Trial name
- NCT04428411
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 486 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE READY (NCT03410992)
- Testing
- Bimekizumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 435 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
- Trial name
- NCT02749799
- Testing
- DFD-01 (betamethasone dipropionate) Spray, 0.05%
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Primus Pharmaceuticals
Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
- Trial name
- NCT05020249
- Testing
- bimekizumab
- Where
- 9 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- UCB Biopharma SRL
Plaque Psoriasis
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
This Phase 3 study has been designed to determine and compare the efficacy and safety of 000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT01882647
- Testing
- 000-0551 Lotion, Vehicle Lotion
- Where
- 11 sites in United States
- Volunteers
- 222 people
- Sponsor
- Therapeutics, Inc.
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Dental Plaque
A Study to Investigate the Antimicrobial Activity of 2 Test Toothpastes
The aim of this exploratory study is to assess the ability of two test toothpastes containing 0.6% w/w zinc chloride stabilised with sodium citrate in a sodium lauryl sulfate (SLS)-containing base to reduce glycolytic metabolism…
- Trial name
- NCT02856880
- Testing
- Test zinc-IPMP toothpaste, Test zinc non- IPMP toothpaste, Positive control
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psoriasis
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis
This is the first study with GSK2982772, a receptor-interacting protein-1 (RIP1) kinase inhibitor, in subjects with active plaque-type psoriasis (PsO).
- Trial name
- NCT02776033
- Testing
- GSK2982772
- Where
- 4 sites in Canada
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to…
- Trial name
- NCT01815424
- Testing
- CP-690,550
- Where
- 24 sites in China, South Korea and 1 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Psoriasis
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months…
- Trial name
- NCT00527072
- Testing
- infliximab
- Volunteers
- 217 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Atherosclerosis
Evaluation of Atorvastatin on Atherosclerosis Composition
The purpose of this study is to evaluate the effects of Atorvastatin on the coronary atherosclerosis plaque morphology.
- Trial name
- NCT00576576
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Emory University